FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Clin Vaccine Immunol / Evaluation of Cross-Protection of a Lineage 1 West Nile Viru...
Clinical and vaccine immunology : CVI2015; 22(9); 1040-1049; doi: 10.1128/CVI.00302-15

Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.

Abstract: Although experimental data regarding cross-protection of horse West Nile virus (WNV) vaccines against lineage 2 infections exist, the cross-protective efficacy of these vaccines under field conditions has not been demonstrated. This study was conducted to evaluate the capability of an inactivated lineage 1 vaccine (Equip WNV) to protect against natural infections from the Nea Santa-Greece-2010 lineage 2 strain. In total, 185 WNV-seronegative horses in Thessaloniki, Greece, were selected during 2 consecutive years (2011 and 2012); 140 were immunized, and 45 were used as controls. Horses were examined for signs compatible with WNV infection. Neutralizing antibody titers against the Greek strain and the PaAn001/France lineage 1 strain were determined in immunized horses. WNV circulation was detected during both years in the study area. It was estimated that 37% and 27% of the horses were infected during 2011 and 2012, respectively. Three control animals developed clinical signs, and the WNV diagnosis was confirmed. Signs related to WNV infection were not observed in the vaccinated animals. The nonvaccinated animals had a 7.58% ± 1.82% higher chance of exhibiting signs than immunized animals (P < 0.05). Neutralizing antibodies raised against both strains in all immunized horses were detectable 1 month after the initial vaccination course. The cross-protective capacity of the lowest titer (1:40) was evident in 19 animals which were subsequently infected and did not exhibit signs. Neutralizing antibodies were detectable until the annual booster, when strong anamnestic responses were observed (geometrical mean titer ratio [GMTR] for lineage 1 of 30.2; GMTR for lineage 2 of 27.5). The results indicate that Equip WNV is capable of inducing cross-protection against natural infections from a virulent lineage 2 WNV strain in horses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Get Full Text
Publication Date: 2015-07-15 PubMed ID: 26178384PubMed Central: PMC4550672DOI: 10.1128/CVI.00302-15Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Controlled Clinical Trial
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines how effectively an inactive West Nile Virus (WNV) vaccine, designed for Lineage 1 of the virus, can protect horses from natural infections of a potent Lineage 2 strain under field conditions.

Research Context and Objective

  • The study acknowledges the experimental data on cross-protection of horse WNV vaccines against lineage 2 infections exists, but states a lack of evidence of such efficacy under field conditions. Thus, the research sought to gauge the capability of an inactivated lineage 1 vaccine, termed Equip WNV, to offer protection against natural infections by Nea Santa-Greece-2010, a lineage 2 strain.

Research Methodology

  • A total of 185 horses in Thessaloniki, Greece, which were WNV-seronegative, were selected over two consecutive years (2011 and 2012) for this study. Of these, 140 were immunized, and 45 were used as control subjects.
  • All the horses were monitored for signs of WNV infection. Neutralizing antibody titers against the Greek strain and the PaAn001/France lineage 1 strain were determined in the immunized horses.

Research Findings

  • There was evidence of WNV circulation in both studied years in the area. During 2011 and 2012, it was estimated that around 37% and 27% of the horses, respectively, got infected.
  • Out of the control animals, three developed clinical signs, and the WNV diagnosis was confirmed. However, signs related to WNV infection were not observed in the vaccinated animals. It was found that non-vaccinated animals had a 7.58% higher chance of exhibiting signs than immunized animals, which was statistically significant (P<0.05).
  • Neutralizing antibodies were raised against both lineage strains in all immunized horses, detectable 1 month after the initial vaccination course. The cross-protective capacity of the lowest titer (1:40) was evident in 19 vaccinated animals which were later infected but did not show clinical signs.
  • The neutralizing antibodies were detectable until the administration of the annual booster, when strong anamnestic responses were observed.

Conclusion

  • This study successfully demonstrated that the Equip WNV vaccine can induce cross-protection against natural infections from a potent lineage 2 WNV strain in horses. This provides supporting evidence in favor of its use in areas where Lineage 2 WNV strain is prevalent.

Cite This Article

APA
Chaintoutis SC, Diakakis N, Papanastassopoulou M, Banos G, Dovas CI. (2015). Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions. Clin Vaccine Immunol, 22(9), 1040-1049. https://doi.org/10.1128/CVI.00302-15

Publication

Clinical and vaccine immunology : CVI
ISSN: 1556-679X
NlmUniqueID: 101252125
Country: United States
Language: English
Volume: 22
Issue: 9
Pages: 1040-1049

Researcher Affiliations

Chaintoutis, Serafeim C
  • Diagnostic Laboratory, Department of Clinical Sciences, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Diakakis, Nikolaos
  • Equine Unit, Companion Animal Clinic, Department of Clinical Sciences, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Papanastassopoulou, Maria
  • Laboratory of Microbiology and Infectious Diseases, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Banos, Georgios
  • Department of Animal Production, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece SRUC, Easter Bush, Midlothian, Scotland, United Kingdom The Roslin Institute, Royal (Dick) School of Veterinary Science, Easter Bush, Midlothian, Scotland, United Kingdom.
Dovas, Chrysostomos I
  • Diagnostic Laboratory, Department of Clinical Sciences, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece dovas@vet.auth.gr.

MeSH Terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Cross Protection
  • Greece
  • Horse Diseases / immunology
  • Horse Diseases / prevention & control
  • Horse Diseases / virology
  • Horses
  • Immunization Schedule
  • Sequence Alignment
  • Time Factors
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / immunology
  • Viral Envelope Proteins / chemistry
  • Viral Envelope Proteins / immunology
  • West Nile Fever / immunology
  • West Nile Fever / prevention & control
  • West Nile Fever / veterinary
  • West Nile Fever / virology
  • West Nile Virus Vaccines / administration & dosage
  • West Nile Virus Vaccines / immunology
  • West Nile virus / classification
  • West Nile virus / immunology
  • West Nile virus / pathogenicity

References

This article includes 63 references
  1. Zeller HG, Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas.. Eur J Clin Microbiol Infect Dis 2004 Mar;23(3):147-56.
    doi: 10.1007/s10096-003-1085-1pubmed: 14986160google scholar: lookup
  2. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease.. Emerg Infect Dis 2005 Aug;11(8):1167-73.
    doi: 10.3201/eid1108.050289apmc: PMC3320478pubmed: 16102302google scholar: lookup
  3. Rappole JH, Hubálek Z. Migratory birds and West Nile virus.. J Appl Microbiol 2003;94 Suppl:47S-58S.
    pubmed: 12675936doi: 10.1046/j.1365-2672.94.s1.6.xgoogle scholar: lookup
  4. Linke S, Niedrig M, Kaiser A, Ellerbrok H, Müller K, Müller T, Conraths FJ, Mühle RU, Schmidt D, Köppen U, Bairlein F, Berthold P, Pauli G. Serologic evidence of West Nile virus infections in wild birds captured in Germany.. Am J Trop Med Hyg 2007 Aug;77(2):358-64.
    pubmed: 17690413
  5. Kramer LD, Styer LM, Ebel GD. A global perspective on the epidemiology of West Nile virus.. Annu Rev Entomol 2008;53:61-81.
    doi: 10.1146/annurev.ento.53.103106.093258pubmed: 17645411google scholar: lookup
  6. Engler O, Savini G, Papa A, Figuerola J, Groschup MH, Kampen H, Medlock J, Vaux A, Wilson AJ, Werner D, Jöst H, Goffredo M, Capelli G, Federici V, Tonolla M, Patocchi N, Flacio E, Portmann J, Rossi-Pedruzzi A, Mourelatos S, Ruiz S, Vázquez A, Calzolari M, Bonilauri P, Dottori M, Schaffner F, Mathis A, Johnson N. European surveillance for West Nile virus in mosquito populations.. Int J Environ Res Public Health 2013 Oct 11;10(10):4869-95.
    doi: 10.3390/ijerph10104869pmc: PMC3823308pubmed: 24157510google scholar: lookup
  7. Dauphin G, Zientara S, Zeller H, Murgue B. West Nile: worldwide current situation in animals and humans.. Comp Immunol Microbiol Infect Dis 2004 Sep;27(5):343-55.
    doi: 10.1016/j.cimid.2004.03.009pubmed: 15225984google scholar: lookup
  8. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease.. Emerg Infect Dis 2005 Aug;11(8):1174-9.
    doi: 10.3201/eid1108.050289bpmc: PMC3320472pubmed: 16102303google scholar: lookup
  9. Cantile C, Di Guardo G, Eleni C, Arispici M. Clinical and neuropathological features of West Nile virus equine encephalomyelitis in Italy.. Equine Vet J 2000 Jan;32(1):31-5.
    doi: 10.2746/042516400777612080pubmed: 10661382google scholar: lookup
  10. Steinman A, Banet C, Sutton GA, Yadin H, Hadar S, Brill A. Clinical signs of West Nile virus encephalomyelitis in horses during the outbreak in Israel in 2000.. Vet Rec 2002 Jul 13;151(2):47-9.
    doi: 10.1136/vr.151.2.47pubmed: 12148602google scholar: lookup
  11. Weese JS, Baird JD, DeLay J, Kenney DG, Staempfli HR, Viel L, Parent J, Smith-Maxie L, Poma R. West Nile virus encephalomyelitis in horses in Ontario: 28 cases.. Can Vet J 2003 Jun;44(6):469-73.
    pmc: PMC340169pubmed: 12839240
  12. Venter M, Human S, Zaayman D, Gerdes GH, Williams J, Steyl J, Leman PA, Paweska JT, Setzkorn H, Rous G, Murray S, Parker R, Donnellan C, Swanepoel R. Lineage 2 west nile virus as cause of fatal neurologic disease in horses, South Africa.. Emerg Infect Dis 2009 Jun;15(6):877-84.
    doi: 10.3201/eid1506.081515pmc: PMC2727306pubmed: 19523285google scholar: lookup
  13. Kutasi O, Bakonyi T, Lecollinet S, Biksi I, Ferenczi E, Bahuon C, Sardi S, Zientara S, Szenci O. Equine encephalomyelitis outbreak caused by a genetic lineage 2 West Nile virus in Hungary.. J Vet Intern Med 2011 May-Jun;25(3):586-91.
    doi: 10.1111/j.1939-1676.2011.0715.xpubmed: 21457323google scholar: lookup
  14. Vazquez A, Sanchez-Seco MP, Ruiz S, Molero F, Hernandez L, Moreno J, Magallanes A, Tejedor CG, Tenorio A. Putative new lineage of west nile virus, Spain.. Emerg Infect Dis 2010 Mar;16(3):549-52.
    doi: 10.3201/eid1603.091033pmc: PMC3322021pubmed: 20202444google scholar: lookup
  15. Bakonyi T, Ivanics E, Erdélyi K, Ursu K, Ferenczi E, Weissenböck H, Nowotny N. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe.. Emerg Infect Dis 2006 Apr;12(4):618-23.
    doi: 10.3201/eid1204.051379pmc: PMC3294705pubmed: 16704810google scholar: lookup
  16. Calistri P, Giovannini A, Hubalek Z, Ionescu A, Monaco F, Savini G, Lelli R. Epidemiology of west nile in europe and in the mediterranean basin.. Open Virol J 2010 Apr 22;4:29-37.
    doi: 10.2174/1874357901004020029pmc: PMC2878979pubmed: 20517490google scholar: lookup
  17. Murgue B, Zeller H, Deubel V. The ecology and epidemiology of West Nile virus in Africa, Europe and Asia.. Curr Top Microbiol Immunol 2002;267:195-221.
    pubmed: 12082990doi: 10.1007/978-3-642-59403-8_10google scholar: lookup
  18. Savini G, Capelli G, Monaco F, Polci A, Russo F, Di Gennaro A, Marini V, Teodori L, Montarsi F, Pinoni C, Pisciella M, Terregino C, Marangon S, Capua I, Lelli R. Evidence of West Nile virus lineage 2 circulation in Northern Italy.. Vet Microbiol 2012 Aug 17;158(3-4):267-73.
    doi: 10.1016/j.vetmic.2012.02.018pubmed: 22406344google scholar: lookup
  19. Marka A, Diamantidis A, Papa A, Valiakos G, Chaintoutis SC, Doukas D, Tserkezou P, Giannakopoulos A, Papaspyropoulos K, Patsoula E, Badieritakis E, Baka A, Tseroni M, Pervanidou D, Papadopoulos NT, Koliopoulos G, Tontis D, Dovas CI, Billinis C, Tsakris A, Kremastinou J, Hadjichristodoulou C, Vakalis N, Vassalou E, Zarzani S, Zounos A, Komata K, Balatsos G, Beleri S, Mpimpa A, Papavasilopoulos V, Rodis I, Spanakos G, Tegos N, Spyrou V, Dalabiras Z, Birtsas P, Athanasiou L, Papanastassopoulou M, Ioannou C, Athanasiou C, Gerofotis C, Papadopoulou E, Testa T, Tsakalidou O, Rachiotis G, Bitsolas N, Mamouris Z, Moutou K, Sarafidou T, Stamatis K, Sarri K, Tsiodras S, Georgakopoulou T, Detsis M, Mavrouli M, Stavropoulou A, Politi L, Mageira G, Christopoulou V, Diamantopoulou G, Spanakis N, Vrioni G, Piperaki ET, Mitsopoulou K, Kioulos I, Michaelakis A, Stathis I, Tselentis I, Psaroulaki A, Keramarou M, Chochlakis D, Photis Y, Konstantinou M, Manetos P, Tsobanoglou S, Mourelatos S, Antalis V, Pergantas P, Eleftheriou G. West Nile virus state of the art report of MALWEST Project.. Int J Environ Res Public Health 2013 Dec 2;10(12):6534-610.
    doi: 10.3390/ijerph10126534pmc: PMC3881129pubmed: 24317379google scholar: lookup
  20. Hellenic Center for Disease Control and Prevention. Report on West Nile virus epidemic. 2013.
  21. Chaintoutis SC, Gewehr S, Danis K, Kalaitzopoulou S, Antalis V, Papanastassopoulou M, Mourelatos S, Panagiotopoulos T, Hadjichristodoulou C, Dovas CI. Surveillance and early warning of West Nile virus lineage 2 using domestic pigeons and backyard chickens. 2014.
  22. Turell MJ, Bunning M, Ludwig GV, Ortman B, Chang J, Speaker T, Spielman A, McLean R, Komar N, Gates R, McNamara T, Creekmore T, Farley L, Mitchell CJ. DNA vaccine for West Nile virus infection in fish crows (Corvus ossifragus).. Emerg Infect Dis 2003 Sep;9(9):1077-81.
    doi: 10.3201/eid0909.030025pmc: PMC3016768pubmed: 14519243google scholar: lookup
  23. Bunning ML, Fox PE, Bowen RA, Komar N, Chang GJ, Speaker TJ, Stephens MR, Nemeth N, Panella NA, Langevin SA, Gordy P, Teehee M, Bright PR, Turell MJ. DNA vaccination of the American crow (Corvus brachyrhynchos) provides partial protection against lethal challenge with West Nile virus.. Avian Dis 2007 Jun;51(2):573-7.
    doi: 10.1637/0005-2086(2007)51[573:DVOTAC]2.0.CO;2pubmed: 17626486google scholar: lookup
  24. Chang GJ, Davis BS, Stringfield C, Lutz C. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection.. Vaccine 2007 Mar 8;25(12):2325-30.
    doi: 10.1016/j.vaccine.2006.11.056pubmed: 17224209google scholar: lookup
  25. Kilpatrick AM, Dupuis AP, Chang GJ, Kramer LD. DNA vaccination of American robins (Turdus migratorius) against West Nile virus.. Vector Borne Zoonotic Dis 2010 May;10(4):377-80.
    doi: 10.1089/vbz.2009.0029pmc: PMC2883478pubmed: 19874192google scholar: lookup
  26. Beck C, Jimenez-Clavero MA, Leblond A, Durand B, Nowotny N, Leparc-Goffart I, Zientara S, Jourdain E, Lecollinet S. Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile disease.. Int J Environ Res Public Health 2013 Nov 12;10(11):6049-83.
    doi: 10.3390/ijerph10116049pmc: PMC3863887pubmed: 24225644google scholar: lookup
  27. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection.. J Infect Dis 2003 Jul 1;188(1):1-4.
    doi: 10.1086/376871pubmed: 12825164google scholar: lookup
  28. Brandler S, Tangy F. Vaccines in development against West Nile virus.. Viruses 2013 Sep 30;5(10):2384-409.
    doi: 10.3390/v5102384pmc: PMC3814594pubmed: 24084235google scholar: lookup
  29. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ. Equine vaccine for West Nile virus.. Dev Biol (Basel) 2003;114:221-7.
    pubmed: 14677692
  30. Seino KK, Long MT, Gibbs EP, Bowen RA, Beachboard SE, Humphrey PP, Dixon MA, Bourgeois MA. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.. Clin Vaccine Immunol 2007 Nov;14(11):1465-71.
    doi: 10.1128/CVI.00249-07pmc: PMC2168174pubmed: 17687109google scholar: lookup
  31. Epp T, Waldner C, Townsend HG. A case-control study of factors associated with development of clinical disease due to West Nile virus, Saskatchewan 2003.. Equine Vet J 2007 Nov;39(6):498-503.
    doi: 10.2746/042516407X248476pubmed: 18065306google scholar: lookup
  32. Intervet Schering-Plough Animal Health. EquiNile with Havlogen: material safety data sheet no. SP002579. .
  33. European Medicines Agency. EPAR product information: Equip WNV. 2015.
  34. European Medicines Agency. EPAR summary for the public: Proteq West Nile. 2015.
  35. Minke JM, Siger L, Cupillard L, Powers B, Bakonyi T, Boyum S, Nowotny N, Bowen R. Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.. Vaccine 2011 Jun 20;29(28):4608-12.
    doi: 10.1016/j.vaccine.2011.04.058pubmed: 21549780google scholar: lookup
  36. Venter M, van Vuren PJ, Mentoor J, Paweska J, Williams J. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice.. Vaccine 2013 Aug 20;31(37):3856-62.
    doi: 10.1016/j.vaccine.2013.06.059pubmed: 23820079google scholar: lookup
  37. Bowen RA, Bosco-Lauth A, Syvrud K, Thomas A, Meinert TR, Ludlow DR, Cook C, Salt J, Ons E. Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine.. Vaccine 2014 Sep 22;32(42):5455-9.
    doi: 10.1016/j.vaccine.2014.07.093pubmed: 25131745google scholar: lookup
  38. Styer LM, Bernard KA, Kramer LD. Enhanced early West Nile virus infection in young chickens infected by mosquito bite: effect of viral dose.. Am J Trop Med Hyg 2006 Aug;75(2):337-45.
    pubmed: 16896145
  39. Chaintoutis SC, Dovas CI, Papanastassopoulou M, Gewehr S, Danis K, Beck C, Lecollinet S, Antalis V, Kalaitzopoulou S, Panagiotopoulos T, Mourelatos S, Zientara S, Papadopoulos O. Evaluation of a West Nile virus surveillance and early warning system in Greece, based on domestic pigeons.. Comp Immunol Microbiol Infect Dis 2014 Mar;37(2):131-41.
    doi: 10.1016/j.cimid.2014.01.004pubmed: 24503179google scholar: lookup
  40. Chaskopoulou A, Dovas CI, Chaintoutis SC, Kashefi J, Koehler P, Papanastassopoulou M. Detection and early warning of West Nile Virus circulation in Central Macedonia, Greece, using sentinel chickens and mosquitoes.. Vector Borne Zoonotic Dis 2013 Oct;13(10):723-32.
    doi: 10.1089/vbz.2012.1176pubmed: 23919609google scholar: lookup
  41. Altman DG. Practical statistics for medical research, 2nd ed Chapman & Hall/CRC tests in statistical science. 2006.
  42. Pagano M, Gauvreau K. Principles of biostatistics, 2nd ed Brooks/Cole, Belmont, CA. 2000.
  43. Deeks JJ, Higgins JPT. Statistical algorithms in Review Manager 5. 2010.
  44. Gilmour AR, Gogel BJ, Cullis BR, Thompson R. ASReml user guide release 3.0. 2009.
  45. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0.. Mol Biol Evol 2013 Dec;30(12):2725-9.
    doi: 10.1093/molbev/mst197pmc: PMC3840312pubmed: 24132122google scholar: lookup
  46. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999 41:95–98.
  47. Chaskopoulou A, Dovas C, Chaintoutis S, Bouzalas I, Ara G, Papanastassopoulou M. Evidence of enzootic circulation of West Nile virus (Nea Santa-Greece-2010, lineage 2), Greece, May to July 2011.. Euro Surveill 2011 Aug 4;16(31).
    pubmed: 21871217
  48. Chaintoutis SC, Chaskopoulou A, Chassalevris T, Koehler PG, Papanastassopoulou M, Dovas CI. West Nile virus lineage 2 strain in Greece, 2012.. Emerg Infect Dis 2013 May;19(5):827-9.
    pmc: PMC3647506pubmed: 23697609doi: 10.3201/eid1905.121418google scholar: lookup
  49. Bouzalas IG, Diakakis N, Chaintoutis SC, Brellou GD, Papanastassopoulou M, Danis K, Vlemmas I, Seuberlich T, Dovas CI. Emergence of Equine West Nile Encephalitis in Central Macedonia, Greece, 2010.. Transbound Emerg Dis 2016 Dec;63(6):e219-e227.
    doi: 10.1111/tbed.12334pubmed: 25660661google scholar: lookup
  50. Long MT, Porter MB, Hernandez J, Giguere S, Fontaine GL, Jodoin EA, Gillis KD. Preliminary data regarding the subclinical exposure rate of horses to West Nile virus during the 2001 Florida enzootic. 2003 p 397–398.
  51. Castillo-Olivares J, Wood J. West Nile virus infection of horses.. Vet Res 2004 Jul-Aug;35(4):467-83.
    doi: 10.1051/vetres:2004022pubmed: 15236677google scholar: lookup
  52. Gardner IA, Wong SJ, Ferraro GL, Balasuriya UB, Hullinger PJ, Wilson WD, Shi PY, MacLachlan NJ. Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California.. Vet Res 2007 Jan-Feb;38(1):109-16.
    doi: 10.1051/vetres:2006045pubmed: 17274156google scholar: lookup
  53. Davidson AH, Traub-Dargatz JL, Rodeheaver RM, Ostlund EN, Pedersen DD, Moorhead RG, Stricklin JB, Dewell RD, Roach SD, Long RE, Albers SJ, Callan RJ, Salman MD. Immunologic responses to West Nile virus in vaccinated and clinically affected horses.. J Am Vet Med Assoc 2005 Jan 15;226(2):240-5.
    doi: 10.2460/javma.2005.226.240pubmed: 15706975google scholar: lookup
  54. Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine.. Vet Immunol Immunopathol 2008 Dec 15;126(3-4):293-301.
    doi: 10.1016/j.vetimm.2008.08.007pubmed: 18838173google scholar: lookup
  55. Pearce MC, Venter M, Schouwstra T, Van Eeden C, Jansen van Vuren P, Paweska J, Liu B, du Plessis A. Serum neutralising antibody response of seronegative horses against lineage 1 and lineage 2 West Nile virus following vaccination with an inactivated lineage 1 West Nile virus vaccine. J South Afr Vet Assoc 2013 84.
    doi: 10.4102/jsava.v84i1.1052google scholar: lookup
  56. Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.. J Virol 2002 Dec;76(24):13097-100.
    pmc: PMC136710pubmed: 12438639doi: 10.1128/jvi.76.24.13097-13100.2002google scholar: lookup
  57. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.. Nat Med 2005 May;11(5):522-30.
    doi: 10.1038/nm1240pmc: PMC1458527pubmed: 15852016google scholar: lookup
  58. Sánchez MD, Pierson TC, McAllister D, Hanna SL, Puffer BA, Valentine LE, Murtadha MM, Hoxie JA, Doms RW. Characterization of neutralizing antibodies to West Nile virus.. Virology 2005 May 25;336(1):70-82.
    doi: 10.1016/j.virol.2005.02.020pubmed: 15866072google scholar: lookup
  59. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.. J Virol 2006 Dec;80(24):12149-59.
    doi: 10.1128/JVI.01732-06pmc: PMC1676294pubmed: 17035317google scholar: lookup
  60. Li L, Barrett AD, Beasley DW. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.. Virology 2005 Apr 25;335(1):99-105.
    doi: 10.1016/j.virol.2005.02.011pubmed: 15823609google scholar: lookup
  61. Crill WD, Chang GJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes.. J Virol 2004 Dec;78(24):13975-86.
    doi: 10.1128/JVI.78.24.13975-13986.2004pmc: PMC533943pubmed: 15564505google scholar: lookup
  62. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.. J Virol 2006 Oct;80(19):9557-68.
    doi: 10.1128/JVI.00080-06pmc: PMC1617264pubmed: 16973559google scholar: lookup
  63. Donadieu E, Bahuon C, Lowenski S, Zientara S, Coulpier M, Lecollinet S. Differential virulence and pathogenesis of West Nile viruses.. Viruses 2013 Nov 22;5(11):2856-80.
    doi: 10.3390/v5112856pmc: PMC3856419pubmed: 24284878google scholar: lookup

Citations

This article has been cited 8 times.
  1. Cavalleri JV, Korbacska-Kutasi O, Leblond A, Paillot R, Pusterla N, Steinmann E, Tomlinson J. European College of Equine Internal Medicine consensus statement on equine flaviviridae infections in Europe.. J Vet Intern Med 2022 Nov;36(6):1858-1871.
    doi: 10.1111/jvim.16581pubmed: 36367340google scholar: lookup
  2. Ganzenberg S, Sieg M, Ziegler U, Pfeffer M, Vahlenkamp TW, Hörügel U, Groschup MH, Lohmann KL. Seroprevalence and Risk Factors for Equine West Nile Virus Infections in Eastern Germany, 2020.. Viruses 2022 May 30;14(6).
    doi: 10.3390/v14061191pubmed: 35746662google scholar: lookup
  3. Desanti-Consoli H, Bouillon J, Chapuis RJJ. Equids' Core Vaccines Guidelines in North America: Considerations and Prospective.. Vaccines (Basel) 2022 Mar 4;10(3).
    doi: 10.3390/vaccines10030398pubmed: 35335029google scholar: lookup
  4. Saiz JC, Martín-Acebes MA, Blázquez AB, Escribano-Romero E, Poderoso T, Jiménez de Oya N. Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation.. Virulence 2021 Dec;12(1):1145-1173.
    doi: 10.1080/21505594.2021.1908740pubmed: 33843445google scholar: lookup
  5. Arfuso F, Giudice E, Di Pietro S, Piccione G, Giannetto C. Modulation of Serum Protein Electrophoretic Pattern and Leukocyte Population in Horses Vaccinated against West Nile Virus.. Animals (Basel) 2021 Feb 11;11(2).
    doi: 10.3390/ani11020477pubmed: 33670395google scholar: lookup
  6. Saiz JC. Animal and Human Vaccines against West Nile Virus.. Pathogens 2020 Dec 21;9(12).
    doi: 10.3390/pathogens9121073pubmed: 33371384google scholar: lookup
  7. Byas AD, Ebel GD. Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.. Pathogens 2020 Jan 7;9(1).
    doi: 10.3390/pathogens9010048pubmed: 31935992google scholar: lookup
  8. Kolodziejek J, Jungbauer C, Aberle SW, Allerberger F, Bagó Z, Camp JV, Dimmel K, de Heus P, Kolodziejek M, Schiefer P, Seidel B, Stiasny K, Nowotny N. Integrated analysis of human-animal-vector surveillance: West Nile virus infections in Austria, 2015-2016.. Emerg Microbes Infect 2018 Mar 14;7(1):25.
    doi: 10.1038/s41426-018-0021-5pubmed: 29535293google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.